Sofosbuvir is absorbed fast in the plasma with a peak concentration (Cmax) at 0.8 to 1 hour after the administered dosage and undergoes extra hepatic metabolism with 61 to 65% bound to human plasma proteins. It is then predominantly converted to the inactive phosphate free circulating metabolite GS-331007 (eliminated 76% through renal passive filtration) which has a median peak plasma concentration at 3.5 to 4 hours after the medication is ingested. Sofosbuvir does not appear to be affected by different levels of macronutrients when compared with fasting states.<unk>  has a maximum concentration at 4 to 4.5 hours after ingestion and is not affected by macronutrients. It is more than 98% protein bound and is predominantly eliminated fecally, with minimal metabolism in the liver. Elimination The median terminal half life after a dosage of<unk>  for 90 mg of 14C-Ledipasvir is 47 hours; for 400 mg of 14C-Sofosbuvir it is 0.5 hours (after the initial distribution of medication in body tissue) and 27 hours (the eventual excretion of the medication). +Steady State (Cmax) Substance ng/mL<unk>  323 Sofosbuvir 618 GS-331007 707 Note: The maximum concentration is 32% higher in healthy individuals than those infected with Hepatitis C. +Mean Steady State AUC0-24 (Area Under the Curve During 24 hours) Substance ng*hr/mL<unk>  7290 Sofosbuvir 1320 GS-33107 12,000 Note: The maximum concentration is 24% higher in healthy individuals than those infected with Hepatitis C. Blood detection An analytical method based on LC tandem MS has been developed for the simultaneous extraction and determination of<unk>  in human plasma using antiviral daclatasvir as an internal standard. Average extraction recoveries for sofosbuvir and<unk>  were 91.61% and 88.93% respectively.
Ledipasvir/sofosbuvir
Atazanavir/ritonavir
Sofosbuvir/velpatasvir
Abacavir/lamivudine
Baloxavir marboxil
Atazanavir/cobicistat
Lamivudine/tenofovir
Fosamprenavir